The U.S.-based drug maker said the additional funding will support its late-stage clinical development including the expanded Phase 3 study of Moderna’s vaccine candidate.
“Encouraged by the Phase 1 data, we believe that our mRNA vaccine may aid in addressing the COVID-19 pandemic and preventing future outbreaks,” Chief Executive Officer Stéphane Bancel said in a press release. The vaccine uses synthetic messenger RNA to inoculate against the coronavirus. Such treatments help the body immunize against a virus and can potentially be developed and manufactured more quickly than traditional vaccines.
Moderna said it remains on track to be able to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, beginning in 2021.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: dailymaverick - 🏆 3. / 84 Read more »
Source: City_Press - 🏆 7. / 72 Read more »
Source: City_Press - 🏆 7. / 72 Read more »
Source: TheCitizen_News - 🏆 6. / 75 Read more »
Source: BDliveSA - 🏆 12. / 63 Read more »
Afrimat proceeds with R116m dividend paymentGroup had delayed decision for its year to end-February due to Covid-19 uncertainty
Source: BDliveSA - 🏆 12. / 63 Read more »